[go: up one dir, main page]

MA31229B1 - Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5 - Google Patents

Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5

Info

Publication number
MA31229B1
MA31229B1 MA32183A MA32183A MA31229B1 MA 31229 B1 MA31229 B1 MA 31229B1 MA 32183 A MA32183 A MA 32183A MA 32183 A MA32183 A MA 32183A MA 31229 B1 MA31229 B1 MA 31229B1
Authority
MA
Morocco
Prior art keywords
benzyl
andlo
trihydro
compounds useful
pde5 inhibitors
Prior art date
Application number
MA32183A
Other languages
Arabic (ar)
English (en)
Inventor
Steffen Weinbrenner
Torsten Dunkern
Degenhard Marx
Beate Schmidt
Thomas Stengel
Dieter Flockerzi
Ulrich Kautz
Daniela Hauser
Jörg Diefenbach
Johannes A M Christiaans
Wiro M P B Menge
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of MA31229B1 publication Critical patent/MA31229B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule (i) dans laquelle r1 à r8 et r11 sont tels que décrits dans la description, leurs sels, les n-oxydes de ces composés et leurs sels, et les stéréoisomères de ces composés, les sels, les n-oxydes de ces composés et les n-oxydes de leurs sels sont des inhibiteurs efficaces de la phosphodiestérase de type 5.
MA32183A 2007-02-05 2009-08-31 Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5 MA31229B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101742A EP1953159A1 (fr) 2007-02-05 2007-02-05 Composés de 6-benzyl-2,3,4,7-tétrahydro-indolo[2,3-c]quinoline en tant qu'inhibiteurs de la PDE5
PCT/EP2008/051076 WO2008095835A1 (fr) 2007-02-05 2008-01-30 Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5

Publications (1)

Publication Number Publication Date
MA31229B1 true MA31229B1 (fr) 2010-03-01

Family

ID=38222238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32183A MA31229B1 (fr) 2007-02-05 2009-08-31 Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5

Country Status (18)

Country Link
US (1) US20100120730A1 (fr)
EP (2) EP1953159A1 (fr)
JP (1) JP2010517958A (fr)
KR (1) KR20090106633A (fr)
CN (1) CN101605791A (fr)
AR (1) AR065157A1 (fr)
AU (1) AU2008212987A1 (fr)
BR (1) BRPI0808378A2 (fr)
CA (1) CA2675357A1 (fr)
EA (1) EA200901034A1 (fr)
IL (1) IL200102A0 (fr)
MA (1) MA31229B1 (fr)
MX (1) MX2009007682A (fr)
NO (1) NO20092902L (fr)
TN (1) TN2009000267A1 (fr)
TW (1) TW200902528A (fr)
WO (1) WO2008095835A1 (fr)
ZA (1) ZA200904440B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820691B2 (en) * 2006-08-28 2010-10-26 Medipropharma, Inc. Indoloquinoline compounds as calcium channel blockers
US20090131442A1 (en) * 2007-11-16 2009-05-21 Joseph Bernstein Method of Treating Bone Pain Caused by Osteoarthritis
WO2010015589A1 (fr) * 2008-08-05 2010-02-11 Nycomed Gmbh Composés hétérocycliques tétracycliques à substitution benzyle comme inhibiteurs de pde5
WO2010015587A1 (fr) * 2008-08-05 2010-02-11 Nycomed Gmbh Composés 5-benzyl-1,2,3,6-tétrahydro-4,6-diaza-cyclopenta[c]fluorène et composés 5-benzyl-1,2,3,6-tétrahydro-4,6-diaza-cyclohepta[c]fluorène
WO2010015588A1 (fr) * 2008-08-05 2010-02-11 Nycomed Gmbh Composés hétérocycliques tétracycliques à substitution benzyle
WO2010015586A2 (fr) * 2008-08-05 2010-02-11 Nycomed Gmbh Composés 2,3,4,7-tétrahydro-indolo[2,3-c]quinoléine
WO2010015585A1 (fr) * 2008-08-05 2010-02-11 Nycomed Gmbh Composés de 6-benzyl-2,3,4,7-tétrahydro-indolo[2,3-c]quinoléine
WO2011015523A1 (fr) 2009-08-03 2011-02-10 Nycomed Gmbh Composés hétérocycliques tétracycliques substitués par benzyle
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4220779B2 (ja) * 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物

Also Published As

Publication number Publication date
KR20090106633A (ko) 2009-10-09
CN101605791A (zh) 2009-12-16
NO20092902L (no) 2009-08-27
AR065157A1 (es) 2009-05-20
TN2009000267A1 (en) 2010-10-18
CA2675357A1 (fr) 2008-08-14
MX2009007682A (es) 2009-07-29
JP2010517958A (ja) 2010-05-27
US20100120730A1 (en) 2010-05-13
TW200902528A (en) 2009-01-16
AU2008212987A1 (en) 2008-08-14
BRPI0808378A2 (pt) 2014-07-01
IL200102A0 (en) 2010-04-15
WO2008095835A1 (fr) 2008-08-14
EP2109610A1 (fr) 2009-10-21
EA200901034A1 (ru) 2010-02-26
ZA200904440B (en) 2010-04-28
EP1953159A1 (fr) 2008-08-06

Similar Documents

Publication Publication Date Title
MA31229B1 (fr) Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31580B1 (fr) Derives de bicyclolactames substitués
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
EA201170769A1 (ru) Органические соединения
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA31419B1 (fr) Derives de pyridine
MA35598B1 (fr) Composition herbicide comprenant du flazasulfuron et un inhibiteur de la protoporphyrinogène oxydase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
PT2057165E (pt) Inibidores de amina ac?clica de fosforilases e hidrolases de nucle?sido
WO2009026179A3 (fr) Composés de proanthocyanidine anti-infectieux et leurs procédés d'utilisation
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
NO20083694L (no) Bruk av rylener som markorer for vaesker
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
TNSN08177A1 (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes